Table 2.
Comparison of anthropometric and biochemical metabolic profile of WD GEP-NET patients under somatostatin analogues (SA positive) treatment versus patients with no somatostatin analogue exposure (SA negative).
| Clinical Features | SA Positive (n = 60) | SA Negative (n = 36) | p |
|---|---|---|---|
| WC (mean/SD) | 96.2 (12.4) | 96.7 (11.3) | 0.198 |
| TG (median (IQR)) | 121.5 (73.3) | 111.0 (91.5) | 0.503 |
| HDL (median (IQR)) | 50.6 (13.3) | 55.7 (12.9) | 0.786 |
| FPG (median (IQR)) | 102.0 (22.0) | 99.5 (20.0) | 0.862 |
| FPI (median (IQR)) | 6.1 (4.0) | 7.3 (9.0) | 0.187 |
| HOMA-R (median (IQR)) | 1.4 (0.8) | 1.5 (2.1) | 0.438 |
WC (waist circumference), TG (Triglycerides), Fasting Glucose (FPG), FPI (fasting plasma insulin), HOMA-IR (Homeostasis Model Assessment Insulin Resistance).